...
首页> 外文期刊>Clinical neuroradiology. >In vivo Metabolic Profiles as Determined by ~31P and short TE ~1H MR-Spectroscopy: No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas
【24h】

In vivo Metabolic Profiles as Determined by ~31P and short TE ~1H MR-Spectroscopy: No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas

机译:通过〜31p和短〜1h MR-spectroscopy确定的体内代谢谱:IDH野生型患者与IDH突变体胶质瘤的患者没有差异

获取原文
获取原文并翻译 | 示例

摘要

Purpose Previous ex vivo spectroscopic data from tissue samples revealed differences in phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH wildtype (IDHwt) gliomas. We investigated whether these changes can be found in vivo using 1H-decoupled 31P magnetic resonance spectroscopic imaging (MRSI) with 3D chemical shift imaging (CSI) at 3 T in patients with low and high-grade gliomas. Methods The study included 33 prospectively enrolled, mostly untreated patients who met spectral quality criteria according to the World Health Organization (WHO II n = 7, WHO III n = 17, WHO IV n = 9; 25 patients IDHmut, 8 patients IDHwt). The MRSI protocol included ~1H decoupled ~31P MRSI with 3D CSI (3D ~31P CSI), 2D ~1H CSI and a ~1H single voxel spectroscopy sequence (TE 30 ms) from the tumor area. For ~1H MRS, absolute metabolite concentration values were calculated (phantom replacement method). For ~31P MRS, metabolite intensity ratios were calculated for the choline (C) and ethanolamine (E)-containing metabolites. Results In our patient cohort we did not find significant differences for the ratio of phosphocholine (PC) and phos-phoethanolamine (PE), PC/PE, (p = 0.24) for IDHmut compared to IDHwt gliomas. Furthermore, we found no elevated ratios of glycerophosphocholine (GPC) and glyc-erophosphoethanolamine (GPE), GPC/GPE, (p = 0.68) or GPC/PE (p = 0.12) for IDHmut gliomas. Even the ratio (PC+GPC)/(PE+GPE) showed no significant differences with respect to mutation status (p = 0.16). Nonetheless, changes related to tumor grade regarding intracellular pH (pHi) and phospholipid metabolism as well as absolute metabolite concentrations of co-registered 2D ~1H CSI data for tumor and control tissue showed the anticipated results. Conclusion Using 3D-CSI data acquisition, in vivo ~31P MR spectroscopic measurement of phospholipid metabolites could not distinguish between IDHmut and IDHwt.
机译:目的以前来自组织样品的离体光谱数据显示了异柠檬酸脱氢酶突变(IDHMUT)和IDH野生型(IDHWT)胶质瘤之间的磷脂代谢物的差异。我们调查了在低级和高级胶质瘤的患者中,使用1H-分离的31P磁共振光谱成像(MRSI)在体内使用带有3D化学移植成像(CSI)的患者。方法该研究包括33次令人前瞻性的注册,主要是未经治疗的患者根据世界卫生组织(WHO II N = 7,WHO IV N = 17,IV N = 9; 25例IDHMUT,8名患者IDHWT)。 MRSI方案包括〜1H与3D CSI(3D〜31P CSI),2D〜1H CSI和来自肿瘤区域的〜1H单voxel光谱序列(TE 30ms)的31p MRSI。对于〜1H MRS,计算绝对代谢物浓度值(幻象替代方法)。对于〜31P的MRS,对胆碱(C)和乙醇胺(E)筛选代谢物来计算代谢物强度比。结果在我们的患者队列中,与IDHWT Gliomas相比,我们对IDHMUT的磷光啉(PC)和Phos-Pho乙醇胺(PE),PC / PE,(P = 0.24)的比例没有找到显着差异。此外,我们发现IDHMUT gliomas的甘油磷磷胆碱(GPC)和GPE),GPC / GPE,(P = 0.68)或GPC / PE(P = 0.12)的GPC / PE)或GPC / PE(P = 0.12)的升高。甚至比率(PC + GPC)/(PE + GPE)也没有关于突变状态的显着差异(P = 0.16)。尽管如此,与细胞内pH(PHI)和磷脂代谢的肿瘤级相关的变化以及用于肿瘤和对照组织的共登记的2D〜1H CSI数据的绝对代谢物浓度显示出预期的结果。结论采用3D-CSI数据采集,在体内〜31p MR光谱测量中的磷脂代谢物不能区分IDHMUT和IDHWT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号